

Remarks

Applicants hereby state that the changes made in the specification do not include new matter. Applicants have amended the specification only to direct the entry of this corrected Sequence Listing at the end of the application and to add SEQ ID NOs to page 99. In compliance with 37 C.F.R. § 1.825(a), Applicants submit substitute sheets to amend the paper copy of the Sequence Listing.

Applicants thank Examiner Schwadron for the courteous and helpful telephonic discussion with Applicants' undersigned representative on June 13, 2002 in reference to an application having a situation similar to the present application. Pursuant to the Examiner's request, Applicants have amended the sequence listing to add the two sequences (SEQ ID NOs:4571 and 4572) from Table III ("DR7 preferred" and "DR7 deleterious," respectively) that contain four or more defined amino acid residues. None of the remaining sequences in Table III contains four or more defined amino acid residues. Support for this amendment is found, *inter alia*, in Table III.

As discussed with the Examiner, none of the sequences in Table II contains four or more defined amino acid residues. Consequently they need not be included in the sequence listing.

In accordance with 37 C.F.R. § 1.825(b), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith are the same.

FIKES *et al.*
Appl. No. 09/458,299

It is respectfully believed this application is now in condition for allowance. Early notice to this effect is earnestly solicited.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Helene C. Carlson
Helene C. Carlson
Agent for Applicants
Registration No. 47,473

Date: July 12, 2002
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

::ODMA\MHODMA\SKGF_DC1;33680;1

SKGF Rev. 1 1/26/01 mac

TABLE III

italicized residues indicate less preferred or “tolerated” residues.